Related Experiment Video
Updated: Aug 14, 2026

Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice
Published on: June 22, 2016
Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A
P J Baker1, J R Hiernaux, M B Fauntleroy
1Laboratory of Microbial Immunity, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
Abstract:
Treatment with nontoxic monophosphoryl lipid A (MPL), which was derived from a polysaccharide-deficient, heptoseless Re mutant of Salmonella typhimurium, was found to inactivate suppressor T-cell activity, as evidenced by a decrease in the degree of low-dose immunological paralysis expressed and an increase in the magnitude of the antibody response to type III pneumococcal polysaccharide. The effects produced, which could not be attributed to the polyclonal activation of immune B cells by MPL, were dependent upon the dose of MPL used, as well as the time when MPL was given relative to low-dose priming or immunization with type III pneumococcal polysaccharide. Neither amplifier nor helper T-cell activity was decreased by treatment with the same, or larger, doses of MPL. The significance of these findings to the use of MPL as an immunological adjuvant or an immunomodulating agent is discussed.
Insights
Nontoxic monophosphoryl lipid A (MPL) treatment inactivates suppressor T-cells, enhancing antibody responses to pneumococcal polysaccharide. These immunomodulatory effects depend on MPL dosage and timing, not B-cell activation.
Area of Science:
- Immunology
- Microbiology
Background:
- Nontoxic monophosphoryl lipid A (MPL) is derived from Salmonella typhimurium.
- Immunological paralysis can be induced by low doses of antigens.
Purpose of the Study:
- To investigate the immunomodulatory effects of MPL on T-cell activity.
- To determine MPL's impact on antibody response to type III pneumococcal polysaccharide.
Main Methods:
- Treatment with MPL in mice.
- Assessing immunological paralysis and antibody response.
- Evaluating T-cell and B-cell activity.
Main Results:
- MPL treatment decreased suppressor T-cell activity.
- MPL increased antibody response to type III pneumococcal polysaccharide.
- MPL effects were dose- and time-dependent and did not involve polyclonal B-cell activation.
Conclusions:
- MPL effectively modulates the immune response by suppressing suppressor T-cells.
- MPL shows potential as an immunological adjuvant or immunomodulating agent.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

